The global Nucleic Acid
Therapeutics CDMO Market size
is expected to reach USD 33.86 billion
by 2030, registering a CAGR of
14.10% during the forecast period, according to a new report by Grand View
Research, Inc. The market's growth is primarily attributed to factors such
as increasing demand for nucleic acid
therapeutics, advancements in
nucleic acid technologies, and rising FDA approvals of nucleic acid
therapeutics, propelling the need for cost-effective contract development and
manufacturing services.
Growing investment
and interest in gene therapy research and development by biotechnology
companies, pharmaceutical firms, and academic institutions are driving the
demand for CDMO services. CDMOs have played a crucial role in gene therapy
manufacturing. For instance, Catalent has taken on the primary role as the
commercial manufacturing partner for Sarepta Therapeutics in their efforts to
advance gene therapy solutions.
The success of
mRNA vaccines in responding to the COVID-19 pandemic has showcased the
potential of nucleic acid therapeutics, stimulating further research and
investment in this field. For instance, in March 2022, Sanofi announced that it
plans to allocate USD 1.02 billion (935 million euros) for the development of
messenger RNA vaccines in France over the coming years. Sanofi intends to
allocate this investment until 2026 as a part of a 2-billion-euro global
investment initiative unveiled in June 2021. This initiative is designed to
expedite the company's mRNA strategy. Such increased funding scenarios drive
market growth.
Furthermore,
increasing incidences of CDMO acquisitions and partnerships are expected to
accelerate the market growth for nucleic acid therapeutics CDMO in the coming
years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98
million (€150 million) to create a cell & gene therapy contract development
and manufacturing organization (CDMO).
The company has
established eureKING, a Special Purpose Acquisition Company (SPAC), with the
aim of merging three European Contract Development and Manufacturing
Organizations (CDMOs) into a unified entity. In another instance, in April
2022, Fujifilm broadened its Advanced Therapies Contract Development and
Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell
therapy manufacturing facility from Atara Biotherapeutics, Inc. located in
California. Such initiatives are expected to boost market growth.
List of Key
Players in the Nucleic Acid Therapeutics CDMO Market
- Agilent Technologies, Inc.
- Curia Global, Inc.
- Ajinomoto Co., Inc.
- Danaher (Aldevron)
- KNC Laboratories Co., Ltd.
- LGC Limited
- Merck KGaA
- WuXi AppTec
- BIOSPRING
- Univercells Inc.
- Exothera
Related Press Release@ Nucleic Acid Therapeutics CDMO Market Report
Nucleic Acid
Therapeutics CDMO Market Report Highlights
- The RNA-based therapies segment held the largest
revenue share in 2023. RNA-based therapies, mainly mRNA, offer versatility
in addressing various diseases. They can be designed to produce a variety
of therapeutic proteins, making them applicable to diverse therapeutic
areas.
- The gene therapy segment is expected to show
significant market growth in the coming years. This is attributed to the
clinical success of gene therapies, which have helped in expanding
indications of gene therapies.
- In 2023, the manufacturing services segment
dominated the market, accounting for over 38.37% of the total revenue
share. Key factors contributing to segment growth include complex
manufacturing processes, scale-up & production challenges, and cost
efficiency.
- The biotechnology companies held a major revenue
share of over 58% in 2023 due to substantial investments in the research
and development of innovative therapies.
- North America held the largest revenue share of
40.24% in the nucleic acid therapeutic CDMO market in 2023. Substantial
investments and funding support, strong academic and research
institutions, and global expansion of CDMOs drive regional growth.
Nucleic Acid Therapeutics CDMO
Market Report Scope
|
Report Attribute |
Details |
|
Market
size value in 2024 |
USD 15.35
billion |
|
Revenue
forecast in 2030 |
USD 33.86
billion |
|
Growth
rate |
CAGR of
14.10% from 2024 to 2030 |
|
Base year
for estimation |
2023 |
|
Historical data |
2018 - 2022 |
|
Forecast period |
2024 - 2030 |
Inquire @ https://www.grandviewresearch.com/inquiry/455661/ibb
Nucleic Acid
Therapeutics CDMO Market Segmentation
Grand View
Research has segmented the global nucleic acid therapeutics CDMO market report
based on type, service, end-use, application, and region:
Nucleic Acid
Therapeutics CDMO Type Outlook (Revenue, USD Million, 2018 - 2030)
- Gene Therapy
- RNA-based Therapies
Nucleic Acid
Therapeutics CDMO Service Outlook (Revenue, USD Million, 2018 - 2030)
- Process Development and Optimization
- Manufacturing Services
- Analytical and Quality Control Services
- Others
Nucleic Acid
Therapeutics CDMO End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Pharmaceutical Companies
- Government & Academic Research Institutes
- Biotech Companies
Nucleic Acid
Therapeutics CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)
- Rare Diseases
- Genetic Disorders
- Infectious Diseases
- Others
Nucleic Acid
Therapeutics CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Explore Horizon, the world's most expansive market
research database
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
